Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 13/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.49 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.49 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.49 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.49 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.49 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.49 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.49 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.49 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.49 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.49 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.49 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.49 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.49 |
| ▸ | PSMA8 | Q8TAA3 | 2/20 | 0.49 |
| ▸ | PSMB7 | Q99436 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927496 | 0.95 | OPRK1 (0.60) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11927495 | 0.92 | OPRK1 (0.55) | OPRK1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL20363366 | 0.90 | OPRK1 (0.49) | OPRK1PSMB5PSMB8 | |
| SCHEMBL10316471 | 0.90 | OPRK1 (0.59) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13290914 | 0.90 | OPRK1 (0.59) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL22957113 | 0.88 | TMPRSS11D (0.52) | OPRK1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL20363353 | 0.88 | OPRK1 (0.57) | OPRK1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21886333 | 0.88 | OPRK1 (0.72) | OPRK1PSMB5 | |
| SCHEMBL11927500 | 0.88 | OPRK1 (0.72) | OPRK1PSMB5 | |
| SCHEMBL11927499 | 0.88 | OPRK1 (0.70) | OPRK1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020855-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885PSMB5 4100/4885PSMB11 4679/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | OPRK1 1/4885PSMB5 992/4885PSMB11 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.